Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Efficacy of anti-HER2 drugs in the treatment of patients with HER2-mutated cancers: a systematic review and meta-analysis

Published:2023-04-30 Issue:7 Volume:23 Page:3205-3216
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Zheng Yonghui,Shen Guoshuang,Zhang Chengrong,Huo Xingfa,Xin Yuanfang,Fang Qianqian,Guan Yumei,Zhao Fuxing,Ren Dengfeng,Liu Zhen,Wang Miaozhou,Zhao Jiuda

Funder

This work was supported by Central Government Guiding Local Scientific and Technological Development Funds for Qinghai Province in China.

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10238-023-01072-7.pdf

Reference58 articles.

1. Cen S, Liu Z, Pan H, Han W. Clinicopathologic features and treatment advances in cancers with HER2 alterations. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188605.

2. Yu X, Ji X, Su C. HER2-altered non-small cell lung cancer: biology, clinicopathologic features, and emerging therapies. Front Oncol. 2022;12:860313.

3. Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacol Ther. 2019;199:188–96.

4. Pahuja KB, Nguyen TT, Jaiswal BS, et al. Actionable activating oncogenic ERBB2/HER2 transmembrane and juxtamembrane domain mutations. Cancer Cell. 2018;34(5):792-806.e5.

5. Profiling Differential Responses to Pan-HER Inhibition. Cancer Discov 2017;7(6), OF12.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor-type agnostic, targeted therapies make a new step forward: The first tumor-agnostic approval of a HER2-targeted therapy;Biomolecules and Biomedicine;2024-07-28

2. Modeling the management of patients with human epidermal growth factor receptor 2-positive breast cancer with liquid biopsy: the future of precision medicine;Current Opinion in Oncology;2024-07-16

3. Targetable ERBB2/HER2 Mutations in Gynecologic Malignancies: Clinicopathological, Immunohistochemical, and Molecular Correlations;International Journal of Gynecological Pathology;2024-06-10

4. The role of molecular diagnostics in the choice of therapy for biliary tract cancers;Siberian journal of oncology;2024-03-21

5. HER2 phosphorylation induced by TGF-β promotes mammary morphogenesis and breast cancer progression;Journal of Cell Biology;2024-02-26